ABUS Market Cap History
Below is a table of the ABUS market cap history going back to 11/15/2010:

Date ABUS Market Cap
11/15/201072.78M
12/31/201048.59M
2/28/201151.19M
10/31/201120.65M
12/31/201118.22M
5/31/201230.10M
12/31/201270.95M
1/3/201370.80M
9/30/2013101.15M
2/28/2014406.58M
3/21/2014568.62M
5/8/2014256.31M
8/12/2014411.39M
10/30/2014378.00M
3/9/2015831.23M
4/30/2015838.85M
7/31/2015588.38M
10/31/2015300.13M
2/29/2016172.62M
4/30/2016270.40M
7/31/2016224.12M
10/31/2016172.75M
3/14/2017151.31M
4/30/2017187.08M
7/31/2017189.84M
10/31/2017311.04M
3/6/2018415.48M
4/30/2018449.37M
7/31/2018614.99M
10/31/2018235.22M
3/5/2019239.64M

Also see: ABUS Shares Outstanding History
and ABUS YTD Return
ABUS Historical Market Cap:
+15.43% CAGR
ABUS Historical Market Cap: +15.43% CAGR

Mouse over chart for data details
11/15/2010 ...3/5/2019
Arbutus Biopharma is a therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection. Co.'s HBV pipeline consists of multiple drug candidates, with differing and complementary mechanisms of action. The candidates include: RNAi 1.0 (ARB-1467), which is Co.'s main RNA Interference (RNAi) HBV candidate designed to block production of the viral proteins including HBV surface antigen expression in patients with HBV; RNAi 2.0 (ARB-1740), Co.'s second RNAi HBV candidate; and Capsid Inhibitors (AB-423 & AB-506), which is being developed as oral therapeutics for the treatment of chronic HBV infection. We show 31 historical shares outstanding datapoints in our ABUS shares outstanding history coverage, used to compute ABUS market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing ABUS market cap history over the course of time is important for investors interested in comparing ABUS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of ABUS versus a peer is one thing; comparing ABUS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like ABUS can fluctuate over the course of history. With this page we aim to empower investors researching ABUS by allowing them to research the ABUS market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ABUS:
ABUS SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Arbutus Biopharma (ABUS) is categorized under the Miscellaneous sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

ACA Market Cap History
ACIU Market Cap History
ACN Market Cap History
ACWF Market Cap History
ACWV Market Cap History
ADIL Market Cap History
ADNT Market Cap History
AEYE Market Cap History
AFIN Market Cap History
AFMD Market Cap History
More Miscellaneous companies »

 

ABUS Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.